Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efepoetin Alfa in Healthy Caucasian and Asian Volunteers
NCT06490939Phase 1Completed
- Sponsor
- Genexine
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 1, open-label trial of epoetin alfa in anemia (2 arms), sponsored by Genexine. Primary endpoints: Maximum Plasma Concentration up to 4 weeks and Area Under the Curve to the last measurable concentration up to 4 weeks. Started Oct 2024; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT06490939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490939.